|

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

RECRUITINGSponsored by Institut fuer Frauengesundheit
Actively Recruiting
SponsorInstitut fuer Frauengesundheit
Started2026-02-19
Est. completion2026-09
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07531693

Summary

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Femal patients age 18 or older at time of informed consent
* Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
* Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
* Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025

Exclusion Criteria:

* Locally advanced or metastatic breast cancer
* Male patients
* Patients with contraindication(s) for abemaciclib therapy according to SmPC

Conditions3

Breast CancerCancerHR+/HER2- Early Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.